1. Home
  2. Stocks
  3. Aplltd Share Price
  • Chart
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs

    • Alembic Pharmaceuticals Share Price

    Large Cap
    ₹1,242.85
    + 1.7 (0.14%)
    06 October, 2024 15:03 BSE: 533573 NSE: APLLTD ISIN: INE901L01018

    Start SIP in Alembic Pharmaceuticals

    Start SIP

    Alembic Pharmaceuticals Performance

    Day Range

    • Low 1,219
    • High 1,275
    ₹ 1,242

    52 Week Range

    • Low 707
    • High 1,285
    ₹ 1,242
    • Open Price1,244
    • Previous Close1,241
    • Volume586218

    Alembic Pharmaceuticals Chart

    • Over 1 Month + 8.34%
    • Over 3 Month + 25.66%
    • Over 6 Month + 23.23%
    • Over 1 Year + 60.18%

    Alembic Pharmaceuticals Key Statistics

    P/E Ratio 38.8
    PEG Ratio 2
    Market Cap Cr 24,430
    Price to Book Ratio 5.1
    EPS 33.9
    Dividend 0.9
    Relative Strength Index 62.16
    Money Flow Index 79.84
    MACD Signal 20.08
    Average True Range 52.84

    Alembic Pharmaceuticals Investment Rating

    • Master Rating:

    • Alembic Pharmaceuticals has an operating revenue of Rs. 6,304.21 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 10% is healthy, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 24% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 2% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 44 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Alembic Pharmaceuticals Financials
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,4761,4751,5881,4791,3321,307
    Operating Expenses Qtr Cr 1,1841,1861,2511,2711,1671,138
    Operating Profit Qtr Cr 291288337207166169
    Depreciation Qtr Cr 696969676674
    Interest Qtr Cr 131015151414
    Tax Qtr Cr 37142300-47
    Net Profit Qtr Cr 17620223313498131
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 5,9055,153
    Operating Expenses Annual Cr 4,8764,485
    Operating Profit Annual in Cr 999664
    Depreciation Cr 271273
    Interest Annual Cr 5449
    Tax Annual Cr 38-1
    Net Profit Annual Cr 666347
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 773730
    Cash from Investing Activity Annual Cr -329-461
    Cash from Financing Annual Activity Cr -445-261
    Net Cash Flow Annual Cr -28
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 4,9094,414
    Fixed Assets Annual Cr 3,0602,979
    Total Non Current Assets Annual Cr 3,4103,350
    Total Current Assets Annual Cr 2,9892,780
    Total Assets Annual Cr 6,3996,130
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 250225
    ROE Annual % 148
    ROCE Annual % 159
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1813
    IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Oper Rev Qtr Cr 1,5621,5171,6311,5951,4861,406
    Operating Expenses Qtr Cr 1,3251,2571,3641,3871,2871,194
    Operating Profit Qtr Cr 237260266208199212
    Depreciation Qtr Cr 696969686674
    Interest Qtr Cr 131115161414
    Tax Qtr Cr 2254-29-36
    Net Profit Qtr Cr 135178180137121153
    IndicatorMar 2024Mar 2023
    Total Revenue Annual Cr 6,2575,655
    Operating Expenses Annual Cr 5,2954,944
    Operating Profit Annual in Cr 933708
    Depreciation Cr 273275
    Interest Annual Cr 5650
    Tax Annual Cr 1613
    Net Profit Annual Cr 616342
    IndicatorMar 2024Mar 2023
    Cash from Operating Activity Annual Cr 803724
    Cash from Investing Activity Annual Cr -321-448
    Cash from Financing Annual Activity Cr -438-262
    Net Cash Flow Annual Cr 4514
    IndicatorMar 2024Mar 2023
    Total ShareHolders Funds Annual Cr 4,8184,370
    Fixed Assets Annual Cr 3,0713,000
    Total Non Current Assets Annual Cr 3,3673,273
    Total Current Assets Annual Cr 3,0792,910
    Total Assets Annual Cr 6,4466,183
    IndicatorMar 2024Mar 2023
    Book Value Per Share Annual Rs 245222
    ROE Annual % 138
    ROCE Annual % 1410
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 1513
    Invest in Alembic Pharmaceuticals

    Alembic Pharmaceuticals Technicals

    EMA & SMA

    Current Price
    ₹1,242.85
    + 1.7 (0.14%)
    pointer
    • Bullish Moving Average
    • ___
    • 16
    • Bearish Moving Average
    • ___
    • 0
    • 20 Day
    • ₹1,183.80
    • 50 Day
    • ₹1,140.22
    • 100 Day
    • ₹1,084.01
    • 200 Day
    • ₹1,001.26
    • 20 Day
    • ₹1,191.98
    • 50 Day
    • ₹1,156.14
    • 100 Day
    • ₹1,053.48
    • 200 Day
    • ₹998.95

    Alembic Pharmaceuticals Resistance and Support

    PIVOT
    ₹1,245.45
    Resistance
    First Resistance 1,272.25
    Second Resistance 1,301.65
    Third Resistance 1,328.45
    RSI 62.16
    MFI 79.84
    MACD Single Line 20.08
    MACD 24.26
    Support
    First Support 1,216.05
    Second Support 1,189.25
    Third Supoort 1,159.85

    Alembic Pharmaceuticals Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 628,704 16,239,424 25.83
    Week 490,188 11,524,320 23.51
    1 Month 502,189 13,036,821 25.96
    6 Month 343,575 10,640,524 30.97

    Alembic Pharmaceuticals Result Highlights

    Alembic Pharmaceuticals Synopsis

    NSE-Medical-Generic Drugs

    Alembic Pharmaceutic is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 5874.06 Cr. and Equity Capital is Rs. 39.31 Cr. for the Year ended 31/03/2024. Alembic Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 16/06/2010 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ2010PLC061123 and registration number is 061123.
    Market Cap 24,430
    Sales 6,017
    Shares in Float 5.90
    No of funds 208
    Yield 0.89
    Book Value 4.98
    U/D Vol ratio 2
    LTDebt / Equity
    Alpha 0.13
    Beta 0.74

    Alembic Pharmaceuticals Shareholding Pattern

    Owner NameJun-24Mar-24Dec-23Sep-23
    Promoters 69.61%69.61%69.61%69.61%
    Mutual Funds 8.05%7.82%7.71%7.33%
    Insurance Companies 6.98%7.1%6.52%6.57%
    Foreign Portfolio Investors 4.32%4.46%4.52%4.51%
    Financial Institutions/ Banks 0.03%0.03%0.03%0.03%
    Individual Investors 7.48%7.41%8%8.24%
    Others 3.53%3.57%3.61%3.71%

    Alembic Pharmaceuticals Management

    Name Designation
    Mr. Chirayu Amin Chairman & CEO
    Mr. Pranav Amin Managing Director
    Mr. Shaunak Amin Managing Director
    Mr. R K Baheti Director - Finance & CFO
    Dr. Archana Hingorani Independent Director
    Mr. Ashok Barat Independent Director
    Mr. Jai Diwanji Independent Director
    Mr. Manish Kejriwal Independent Director

    Alembic Pharmaceuticals Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Alembic Pharmaceuticals Corporate Action

    Date Purpose Remarks
    2024-08-08 Quarterly Results
    2024-05-09 Audited Results & Final Dividend
    2024-02-05 Quarterly Results
    2023-11-07 Quarterly Results
    2023-08-04 Quarterly Results
    Date Purpose Remarks
    2024-07-15 FINAL Rs.11.00 per share(550%)Final Dividend
    2023-07-28 FINAL Rs.8.00 per share(400%)Final Dividend
    2022-08-18 INTERIM Rs.10.00 per share(500%)Dividend (Changed Final Dividend as Interim Divided)

    Alembic Pharmaceuticals MF Shareholding

    Name Amount(cr)
    Axis Small Cap Fund Regular Growth 23,772
    DSP Midcap Fund Growth 20,069
    Kotak Small Cap Growth 17,639
    DSP ELSS Tax Saver Fund Regular Plan Growth 17,488
    HDFC Multi Cap Fund Regular Growth 17,186

    Alembic Pharmaceuticals FAQs

    What is Share Price of Alembic Pharmaceuticals ?

    Alembic Pharmaceuticals share price is ₹1,242 As on 06 October, 2024 | 14:49

    What is the Market Cap of Alembic Pharmaceuticals ?

    The Market Cap of Alembic Pharmaceuticals is ₹24429.8 Cr As on 06 October, 2024 | 14:49

    What is the P/E ratio of Alembic Pharmaceuticals ?

    The P/E ratio of Alembic Pharmaceuticals is 38.8 As on 06 October, 2024 | 14:49

    What is the PB ratio of Alembic Pharmaceuticals ?

    The PB ratio of Alembic Pharmaceuticals is 5.1 As on 06 October, 2024 | 14:49

    Q2FY23
    Open Free Demat Account

    Be a part of 5paisa community - The first listed discount broker of India.

    +91
     
    footer_form

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI-registered Mutual Fund Distributor | AMFI REGN No.: ARN-104096 | Date of initial Registration: 30/07/2015 | Current validity of ARN : 30/07/2027 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of ₹10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of ₹10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support Desk Helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.

    Email: support@5paisa.com

    Support Desk Helpline: 8976689766

    ©2024, 5paisa Capital Ltd. All Rights Reserved. We are ISO 27001:2013 Certified.